Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This oral fixed-dose combination product developed by Kriam Pharma contains aceclofenac, paracetamol, and serratiopeptidase. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of prostaglandins involved in pain and inflammation. Paracetamol serves as an analgesic and antipyretic, likely acting through central COX inhibition and modulation of endogenous cannabinoid pathways to elevate the pain threshold. Serratiopeptidase is a proteolytic enzyme derived from Serratia species that facilitates the breakdown of abnormal proteins such as fibrin and bradykinin at the site of injury. This enzymatic action helps reduce edema, improve microcirculation, and accelerate tissue repair. The combination is indicated for the symptomatic management of pain and inflammation in conditions like osteoarthritis, rheumatoid arthritis, and post-traumatic or post-operative edema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclofenac + paracetamol + serratiopeptidase.